condition found
Features: Therapy |
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range. The main pathways affected are: Calcium Signaling: -influence the activity of voltage-gated calcium channels. Oxidative Stress and Reactive Oxygen Species (ROS) Pathways Heat Shock Proteins (HSPs) and Cellular Stress Responses Cell Proliferation and Growth Signaling: MAPK/ERK pathway. Gene Expression and Epigenetic Modifications: NF-κB Angiogenesis Pathways: VEGF (improving VEGF for normal cells) PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models Pathways: - most reports have ROS production increasing in cancer cells , while decreasing in normal cells. - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells), - cause Cell cycle arrest : TumCCA↑, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, - inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓, - Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol). - Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
Source: |
Type: |
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
2018- | CAP,  | MF,  |   | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
- | Review, | HCC, | NA |
2260- | MF,  |   | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
- | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
2244- | MF,  |   | Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer |
- | Review, | Var, | NA |
2237- | MF,  |   | The Effect of Pulsed Electromagnetic Field Stimulation of Live Cells on Intracellular Ca2+ Dynamics Changes Notably Involving Ion Channels |
- | in-vitro, | AML, | KG-1 | - | in-vitro, | Nor, | HUVECs |
3480- | MF,  |   | Cellular and Molecular Effects of Magnetic Fields |
- | Review, | NA, | NA |
3478- | MF,  |   | One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study |
- | Trial, | BC, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | C2C12 |
2261- | MF,  |   | Tumor-specific inhibition with magnetic field |
- | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
507- | MF,  |   | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
- | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
501- | MF,  |   | Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
512- | MF,  |   | Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | FF95 |
534- | MF,  |   | Effect of extremely low frequency electromagnetic field parameters on the proliferation of human breast cancer |
- | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | Nor, | MCF10 |
532- | MF,  |   | A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
526- | MF,  |   | Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels |
- | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | HeLa | - | vitro+vivo, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | HEK293 |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:172 Target#:1110 State#:% Dir#:%
wNotes=on sortOrder:rid,rpid